Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Monte Rosa Therapeutics, Inc.GLUE · Entity 4828 | Chief Business & Legal Officer | April 09, 2026 | April 10, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Monte Rosa Therapeutics, Inc.
Report date April 09, 2026 · Filed April 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 55,000 |
Reported balance
After 2026-04-09 transaction · row 1
1 source rowRow 1 · 2026-04-09 · Sale · Disposed 5,845 · Balance 55,000 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.6901 to $17.71, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.6901 to $17.71, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 09, 2026 Filed Apr 10, 2026 20:07 UTC | Monte Rosa Therapeutics, Inc. GLUE · Entity 4828 | SaleCommon Stock | 5,845 | $17.69 | $103,412.66 |
DisclosureSEC source: 0001193125-26-151254 · ownership.xml · nonDerivative · entry 1 Nickson Philip · CIK 0001911369 · Chief Business & Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.6901 to $17.71, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| January 05, 2026 Filed Jan 5, 2026 21:06 UTC | Monte Rosa Therapeutics, Inc. GLUE · Entity 4828 | SaleCommon Stock | 3,155 | $15.17 | $47,861.35 |
DisclosureSEC source: 0001193125-26-002406 · ownership.xml · nonDerivative · entry 2 Nickson Philip · CIK 0001911369 · Chief Business & Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,845 F2 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.17 to $15.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| January 02, 2026 Filed Jan 5, 2026 21:06 UTC | Monte Rosa Therapeutics, Inc. GLUE · Entity 4828 | GrantStock Option (Right to Buy) · Derivative | 126,000 | $0.00 Strike: $15.31 | $0.00 |
DisclosureSEC source: 0001193125-26-002406 · ownership.xml · derivative · entry 3 Nickson Philip · CIK 0001911369 · Chief Business & Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 126,000 Underlying: Common Stock · 126,000 shares Expires 2036-01-01 F4 · derivative.exercise_date: 25% of this option shall vest and become exercisable on January 2, 2027, with the remainder vesting in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| January 02, 2026 Filed Jan 5, 2026 21:06 UTC | Monte Rosa Therapeutics, Inc. GLUE · Entity 4828 | GrantCommon Stock | 28,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-002406 · ownership.xml · nonDerivative · entry 1 Nickson Philip · CIK 0001911369 · Chief Business & Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,000 F1 · price: Represents restricted stock units ("RSUs") granted under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 25% of the RSUs shall vest on January 2, 2027, with the remainder vesting in 3 equal annual installments thereafter, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 21:15 UTC | Monte Rosa Therapeutics, Inc. GLUE · Entity 4828 | GrantStock Option (Right to Buy) · Derivative | 161,000 | $0.00 Strike: $7.11 | $0.00 |
DisclosureSEC source: 0000950170-25-002105 · ownership.xml · derivative · entry 2 Nickson Philip · CIK 0001911369 · Chief Business & Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 161,000 Underlying: Common Stock · 161,000 shares Expires 2035-01-01 F2 · derivative.exercise_date: 25% of this option shall vest and become exercisable on January 1, 2026, with the remainder vesting in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 21:15 UTC | Monte Rosa Therapeutics, Inc. GLUE · Entity 4828 | GrantCommon Stock | 36,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-002105 · ownership.xml · nonDerivative · entry 1 Nickson Philip · CIK 0001911369 · Chief Business & Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,000 F1 · shares: Represents restricted stock units ("RSUs") granted under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 25% of the RSUs shall vest on January 1, 2026, with the remainder vesting in 3 equal annual installments thereafter, subject to the Reporting Person's continued service on each such vesting date. F1 · price: Represents restricted stock units ("RSUs") granted under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 25% of the RSUs shall vest on January 1, 2026, with the remainder vesting in 3 equal annual installments thereafter, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 20:10 UTC | Monte Rosa Therapeutics, Inc. GLUE · Entity 4828 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $3.98 | $0.00 |
DisclosureSEC source: 0000950170-24-069309 · ownership.xml · derivative · entry 1 Nickson Philip · CIK 0001911369 · Chief Business & Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2034-06-03 F1 · derivative.exercise_date: 25% of this option shall vest and become exercisable on May 28, 2025, with the remainder vesting in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 21:15 UTC | Monte Rosa Therapeutics, Inc. GLUE · Entity 4828 | GrantStock Option (Right to Buy) · Derivative | 109,000 | $0.00 Strike: $5.71 | $0.00 |
DisclosureSEC source: 0001209191-24-000769 · doc4.xml · derivative · entry 1 Nickson Philip · CIK 0001911369 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 109,000 Underlying: Common Stock · 109,000 shares Expires 2034-01-01 F1 · derivative.exercise_date: 25% of this option shall vest and become exercisable on January 1, 2025, with the remainder vesting in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| January 03, 2023 Filed Jan 4, 2023 21:31 UTC | Monte Rosa Therapeutics, Inc. GLUE · Entity 4828 | GrantStock Option (Right to Buy) · Derivative | 123,650 | $0.00 Strike: $7.78 | $0.00 |
DisclosureSEC source: 0001209191-23-000957 · doc4.xml · derivative · entry 1 Nickson Philip · CIK 0001911369 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,650 Underlying: Common Stock · 123,650 shares Expires 2033-01-02 F1 · derivative.exercise_date: 25% of this option shall vest and become exercisable on January 1, 2024, with the remainder vesting in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| March 01, 2022 Filed Mar 2, 2022 23:43 UTC | Monte Rosa Therapeutics, Inc. GLUE · Entity 4828 | GrantStock Option (Right to Buy) · Derivative | 70,600 | $0.00 Strike: $13.41 | $0.00 |
DisclosureSEC source: 0000899243-22-008698 · doc4.xml · derivative · entry 1 Nickson Philip · CIK 0001911369 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,600 Underlying: Common Stock · 70,600 shares Expires 2032-02-29 F1 · derivative.exercise_date: 25% of this option shall vest and become exercisable on January 1, 2023, with the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.